Log in
OTCMKTS:DMCAF

DiaMedica Therapeutics Stock Forecast, Price & News

$4.31
+0.10 (+2.38 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$4.17
Now: $4.31
$4.49
50-Day Range
$0.38
MA: $4.28
$4.86
52-Week Range
$0.38
Now: $4.31
$0.38
Volume10,664 shs
Average Volume131,151 shs
Market Capitalization$677.27 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.02
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.42 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:DMCAF
CUSIPN/A
CIKN/A
Phone763-496-5454
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$677.27 million
Next Earnings DateN/A
OptionableNot Optionable
$4.31
+0.10 (+2.38 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DMCAF News and Ratings via Email

Sign-up to receive the latest news and ratings for DMCAF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











DiaMedica Therapeutics (OTCMKTS:DMCAF) Frequently Asked Questions

Who are some of DiaMedica Therapeutics' key competitors?

Who are DiaMedica Therapeutics' key executives?

DiaMedica Therapeutics' management team includes the following people:
  • Mr. Rick Pauls MBA, CEO, Pres & Director (Age 47)
  • Dr. Todd A. Verdoorn Ph.D., Chief Scientific Officer
  • Mr. Scott B. Kellen, CFO & Company Sec. (Age 53)
  • Mr. Edward B. Rady, Chief Commercial Advisor (Age 69)
  • Dr. Dennis D. Kim M.D., MBA, Consulting Chief Medical Officer (Age 48)

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the OTCMKTS under the ticker symbol "DMCAF."

How do I buy shares of DiaMedica Therapeutics?

Shares of DMCAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DiaMedica Therapeutics' stock price today?

One share of DMCAF stock can currently be purchased for approximately $4.31.

How big of a company is DiaMedica Therapeutics?

DiaMedica Therapeutics has a market capitalization of $677.27 million.

What is DiaMedica Therapeutics' official website?

The official website for DiaMedica Therapeutics is www.diamedica.com.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 Carlson Parkway Suite 260, Minneapolis MN, 55447. The company can be reached via phone at 763-496-5454 or via email at [email protected]

This page was last updated on 10/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.